Cyclerion Therapeutics Trading Near Cash; Offers A Favorable Risk Reward Opportunity
- Friday, November 1, 2019, 3:35
- Market
- Add a comment
The company evaluated praliciguat in 2 diseases, diabetic nephropathy and HFpEF, which are very complex and difficult-to-treat.
About the Author
admin123 has written 23404 stories on this site.
